Market Overview:
The global Ganirelix market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of polycystic ovaries syndrome (PCOS), increasing demand for fertility treatments, and growing awareness about infertility treatments. The global Ganirelix market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into patent and generic. The patent segment is expected to account for a larger share of the global Ganirelix market in 2018 owing to its longer shelf life and higher price point as compared to generic drugs. However, over time, as more generics enter the market, their prices are likely to drop which could lead to a decline in their share over time. On the basis of application, PCOS accounts for a majority share ofthe global Ganirelixmarket followed by ovarian stimulation and orthostatic intolerance.
Product Definition:
Ganirelix is a GnRH antagonist used to prevent premature LH surges in women undergoing assisted reproductive technology (ART) such as in vitro fertilization. It is also used to manage endometriosis. Ganirelix binds to the GnRH receptor, preventing the action of endogenous GnRH and therefore LH release.
Patent:
Patent is a legal right granted to an original discoverer or innovator for a discovery or an invention. The patent system is designed in such a way that it protects the rights of the inventors and gives them exclusive rights over their discoveries for limited time. After expiration of the period specified, others are required to comply with the norms stated by patents.
Generic:
Ganirelix (ganoderma) is a type of fungus that lives in the pores of the bark of trees and other plants. It was first discovered in Japan, where it grows in association with oaks. The fungus has been used for centuries by Japanese people to treat diseases related to skin and bones.
Application Insights:
Polycystic ovary syndrome (PCOS) held the largest market share in 2017. Ganirelix is used in the treatment of polycystic ovary syndrome due to its ability to reduce testosterone and promote ovarian function. Increasing awareness about PCOS and growing number of clinical trials are expected to be major factors driving this segment over the forecast period.
Ovarian stimulation is anticipated to witness lucrative growth over the forecast period owing to increasing infertility cases, which drive demand for assisted reproductive technology procedures such as In-vitro Fertilization (IVF). Ganirelix along with Cetrotide is used for ovarian stimulation in patients undergoing IVF treatment. The introduction of new drugs with improved efficacy coupled with a reduced dosage has ledto an increased usage rate of ganirelix acetate during ovarian stimulation therapy, whichis expectedto beshownin 2030byincreasingly high fertility rates across all age groups and both genders worldwide.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing R&D initiatives and rising healthcare expenditure by government and private sectors. In addition, high prevalence of PCOS in North America has led to an increase in awareness about diagnostic procedures and treatment options, thereby boosting product demand.
Asia Pacific is anticipated to witness a lucrative growth rate during the forecast period due to factors such as improving economic conditions, growing population base with high infertility rates, increased awareness about available treatment options & their benefits as well as low cost of clinical trials for new drug development. These aforementioned factors are expected lead towards an increase in market revenue over the next eight years time frame.
Growth Factors:
- Increasing prevalence of infertility: The global infertility rate is increasing due to various factors such as delayed marriage and parenthood, lifestyle changes, and environmental pollution. This is expected to drive the demand for fertility treatments, including ganirelix therapy.
- Growing awareness about assisted reproductive technologies (ART): There is a growing awareness among couples about the benefits of ART therapies such as ganirelix treatment for overcoming infertility issues. This is likely to boost the demand for ganirelix in the coming years.
- Rising number of single women opting for fertility treatments: There has been a significant rise in the number of single women seeking fertility treatments in recent years owing to various social and economic factors such as delayed marriage and parenthood, career aspirations, and rising cost of traditional family planning methods. This is likely to create robust growth opportunities for the ganirelix market in future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ganirelix Market Research Report
By Type
Patent, Generic
By Application
Polycystic Ovaries Syndrome, Ovarian Stimulation, Orthostatic Intolerance, Controlled Ovarian Stimulation, Infertility
By Companies
Organon, Sun Pharm, Merck Sharp and Dohme (MSD), Ferring Pharmaceuticals, Ambinter, BLD Pharm, Chemenu
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Ganirelix Market Report Segments:
The global Ganirelix market is segmented on the basis of:
Types
Patent, Generic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Polycystic Ovaries Syndrome, Ovarian Stimulation, Orthostatic Intolerance, Controlled Ovarian Stimulation, Infertility
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Organon
- Sun Pharm
- Merck Sharp and Dohme (MSD)
- Ferring Pharmaceuticals
- Ambinter
- BLD Pharm
- Chemenu
Highlights of The Ganirelix Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Patent
- Generic
- By Application:
- Polycystic Ovaries Syndrome
- Ovarian Stimulation
- Orthostatic Intolerance
- Controlled Ovarian Stimulation
- Infertility
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ganirelix Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ganirelix is a drug used to treat anemia. It works by helping the body produce more red blood cells.
Some of the key players operating in the ganirelix market are Organon, Sun Pharm, Merck Sharp and Dohme (MSD), Ferring Pharmaceuticals, Ambinter, BLD Pharm, Chemenu.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ganirelix Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ganirelix Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ganirelix Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ganirelix Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ganirelix Market Size & Forecast, 2018-2028
4.5.1 Ganirelix Market Size and Y-o-Y Growth
4.5.2 Ganirelix Market Absolute $ Opportunity
Chapter 5 Global Ganirelix Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ganirelix Market Size Forecast by Type
5.2.1 Patent
5.2.2 Generic
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ganirelix Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ganirelix Market Size Forecast by Applications
6.2.1 Polycystic Ovaries Syndrome
6.2.2 Ovarian Stimulation
6.2.3 Orthostatic Intolerance
6.2.4 Controlled Ovarian Stimulation
6.2.5 Infertility
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ganirelix Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ganirelix Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ganirelix Analysis and Forecast
9.1 Introduction
9.2 North America Ganirelix Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ganirelix Market Size Forecast by Type
9.6.1 Patent
9.6.2 Generic
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ganirelix Market Size Forecast by Applications
9.10.1 Polycystic Ovaries Syndrome
9.10.2 Ovarian Stimulation
9.10.3 Orthostatic Intolerance
9.10.4 Controlled Ovarian Stimulation
9.10.5 Infertility
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ganirelix Analysis and Forecast
10.1 Introduction
10.2 Europe Ganirelix Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ganirelix Market Size Forecast by Type
10.6.1 Patent
10.6.2 Generic
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ganirelix Market Size Forecast by Applications
10.10.1 Polycystic Ovaries Syndrome
10.10.2 Ovarian Stimulation
10.10.3 Orthostatic Intolerance
10.10.4 Controlled Ovarian Stimulation
10.10.5 Infertility
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ganirelix Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ganirelix Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ganirelix Market Size Forecast by Type
11.6.1 Patent
11.6.2 Generic
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ganirelix Market Size Forecast by Applications
11.10.1 Polycystic Ovaries Syndrome
11.10.2 Ovarian Stimulation
11.10.3 Orthostatic Intolerance
11.10.4 Controlled Ovarian Stimulation
11.10.5 Infertility
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ganirelix Analysis and Forecast
12.1 Introduction
12.2 Latin America Ganirelix Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ganirelix Market Size Forecast by Type
12.6.1 Patent
12.6.2 Generic
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ganirelix Market Size Forecast by Applications
12.10.1 Polycystic Ovaries Syndrome
12.10.2 Ovarian Stimulation
12.10.3 Orthostatic Intolerance
12.10.4 Controlled Ovarian Stimulation
12.10.5 Infertility
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ganirelix Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ganirelix Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ganirelix Market Size Forecast by Type
13.6.1 Patent
13.6.2 Generic
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ganirelix Market Size Forecast by Applications
13.10.1 Polycystic Ovaries Syndrome
13.10.2 Ovarian Stimulation
13.10.3 Orthostatic Intolerance
13.10.4 Controlled Ovarian Stimulation
13.10.5 Infertility
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ganirelix Market: Competitive Dashboard
14.2 Global Ganirelix Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Organon
14.3.2 Sun Pharm
14.3.3 Merck Sharp and Dohme (MSD)
14.3.4 Ferring Pharmaceuticals
14.3.5 Ambinter
14.3.6 BLD Pharm
14.3.7 Chemenu
